{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:04:19Z","timestamp":1790211859012,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T00:00:00Z","timestamp":1494806400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasitol Res"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00436-017-5478-y","type":"journal-article","created":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T19:47:10Z","timestamp":1494877630000},"page":"1793-1799","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Toxoplasma gondii and schizophrenia: a review of published RCTs"],"prefix":"10.1007","volume":"116","author":[{"given":"Sam D.","family":"Chorlton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,15]]},"reference":[{"key":"5478_CR1","doi-asserted-by":"publisher","unstructured":"Amminger GP, McGorry PD, Berger GE et al (2007) Antibodies to infectious agents in individuals at ultrahigh risk for psychosis. Biol Psychiatry 61:1215\u20131217. doi: 10.1016\/j.biopsych.2006.09.034","DOI":"10.1016\/j.biopsych.2006.09.034"},{"key":"5478_CR2","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1128\/AAC.5.6.647","volume":"5","author":"FG Araujo","year":"1974","unstructured":"Araujo FG, Remington JS (1974) Effect of clindamycin on acute and chronic toxoplasmosis in mice. Antimicrob Agents Chemother 5:647\u2013651. doi: 10.1128\/AAC.5.6.647","journal-title":"Antimicrob Agents Chemother"},{"key":"5478_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/BF01963942","volume":"10","author":"FG Araujo","year":"1991","unstructured":"Araujo FG, Shepard RM, Remington JS (1991) In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii. Eur J Clin Microbiol Infect Dis 10:519\u2013524. doi: 10.1007\/BF01963942","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5478_CR4","first-page":"693","volume":"88","author":"E Buentello","year":"1958","unstructured":"Buentello E (1958) Preliminary observations on the relationship between toxoplasmosis, lysergic acid and schizophrenia. Gac Med Mex 88:693\u2013710","journal-title":"Gac Med Mex"},{"key":"5478_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.14411\/fp.2015.015","volume":"62","author":"T \u00c7elik","year":"2015","unstructured":"\u00c7elik T, Kartalci \u015e, Ayta\u015f \u00d6 et al (2015) Association between latent toxoplasmosis and clinical course of schizophrenia\u2014continuous course of the disease is characteristic for Toxoplasma gondii-infected patients. Folia Parasitol 62:15. doi: 10.14411\/fp.2015.015","journal-title":"Folia Parasitol"},{"key":"5478_CR6","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1128\/AAC.38.8.1803","volume":"38","author":"HR Chang","year":"1994","unstructured":"Chang HR, Arsenijevic D, Comte R et al (1994) Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii. Antimicrob Agents Chemother 38:1803\u20131807. doi: 10.1128\/AAC.38.8.1803","journal-title":"Antimicrob Agents Chemother"},{"key":"5478_CR7","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1093\/jac\/27.5.639","volume":"27","author":"HR Chang","year":"1991","unstructured":"Chang HR, Comte R, Piguet PF, Pech\u00e8re JC (1991) Activity of minocycline against Toxoplasma gondii infection in mice. J Antimicrob Chemother 27:639\u2013645. doi: 10.1093\/jac\/27.5.639","journal-title":"J Antimicrob Chemother"},{"key":"5478_CR8","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1128\/AAC.05183-11","volume":"56","author":"WK Chew","year":"2012","unstructured":"Chew WK, Segarra I, Ambu S, Mak JW (2012) Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis. Antimicrob Agents Chemother 56:1762\u20131768. doi: 10.1128\/AAC.05183-11","journal-title":"Antimicrob Agents Chemother"},{"key":"5478_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.schres.2009.05.005","volume":"112","author":"FB Dickerson","year":"2009","unstructured":"Dickerson FB, Stallings CR, Boronow JJ et al (2009) A double-blind trial of adjunctive azithromycin in individuals with schizophrenia who are seropositive for Toxoplasma gondii. Schizophr Res 112:198\u2013199. doi: 10.1016\/j.schres.2009.05.005","journal-title":"Schizophr Res"},{"key":"5478_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.schres.2011.04.010","volume":"129","author":"F Dickerson","year":"2011","unstructured":"Dickerson F, Stallings CR, Vaughan C et al (2011) Artemisinin reduces the level of antibodies to gliadin in schizophrenia. Schizophr Res 129:196\u2013200. doi: 10.1016\/j.schres.2011.04.010","journal-title":"Schizophr Res"},{"key":"5478_CR11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1093\/jac\/dkf251","volume":"50","author":"O Djurkovi\u0107-Djakovi\u0107","year":"2002","unstructured":"Djurkovi\u0107-Djakovi\u0107 O, Milenkovi\u0107 V, Nikoli\u0107 A et al (2002) Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii. J Antimicrob Chemother 50:981\u2013987. doi: 10.1093\/jac\/dkf251","journal-title":"J Antimicrob Chemother"},{"key":"5478_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/jac\/34.1.111","volume":"34","author":"JL Dumas","year":"1994","unstructured":"Dumas JL, Chang R, Mermillod B et al (1994) Evaluation of the efficacy of prolonged administration of azithromycin in a murine model of chronic toxoplasmosis. J Antimicrob Chemother 34:111\u2013118. doi: 10.1093\/jac\/34.1.111","journal-title":"J Antimicrob Chemother"},{"key":"5478_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0924-8579(99)00073-4","volume":"13","author":"JL Dumas","year":"1999","unstructured":"Dumas JL, Pizzolato G, Pech\u00e8re JC (1999) Evaluation of trimethoprim and sulphamethoxazole as monotherapy or in combination in the management of toxoplasmosis in murine models. Int J Antimicrob Agents 13:35\u201339. doi: 10.1016\/S0924-8579(99)00073-4","journal-title":"Int J Antimicrob Agents"},{"key":"5478_CR14","doi-asserted-by":"publisher","first-page":"4450","DOI":"10.1128\/AAC.00502-09","volume":"53","author":"IR Dunay","year":"2009","unstructured":"Dunay IR, Chan WC, Haynes RK, Sibley LD (2009) Artemisone and artemiside control acute and reactivated toxoplasmosis in a murine model. Antimicrob Agents Chemother 53:4450\u20134456. doi: 10.1128\/AAC.00502-09","journal-title":"Antimicrob Agents Chemother"},{"key":"5478_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.exppara.2015.06.005","volume":"157","author":"MM Eissa","year":"2015","unstructured":"Eissa MM, Barakat AMA, Amer EI, Younis LK (2015) Could miltefosine be used as a therapy for toxoplasmosis? Exp Parasitol 157:12\u201322. doi: 10.1016\/j.exppara.2015.06.005","journal-title":"Exp Parasitol"},{"key":"5478_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s11011-016-9822-1","volume":"31","author":"HM Elsheikha","year":"2016","unstructured":"Elsheikha HM, B\u00fcsselberg D, Zhu XQ (2016) The known and missing links between Toxoplasma gondii and schizophrenia. Metab Brain Dis 31:749\u2013759. doi: 10.1007\/s11011-016-9822-1","journal-title":"Metab Brain Dis"},{"key":"5478_CR17","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1242\/jeb.073635","volume":"216","author":"J Flegr","year":"2013","unstructured":"Flegr J (2013) Influence of latent Toxoplasma infection on human personality, physiology and morphology: pros and cons of the Toxoplasma\u2013human model in studying the manipulation hypothesis. J Exp Biol 216:127\u2013133. doi: 10.1242\/jeb.073635","journal-title":"J Exp Biol"},{"key":"5478_CR18","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1586\/14787210.2015.1051033","volume":"13","author":"J Flegr","year":"2015","unstructured":"Flegr J (2015) Schizophrenia and Toxoplasma gondii: an undervalued association? Expert Rev Anti-Infect Ther 13:817\u2013820. doi: 10.1586\/14787210.2015.1051033","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"5478_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jpsychires.2015.02.011","volume":"63","author":"G Fond","year":"2015","unstructured":"Fond G, Boyer L, Gaman A et al (2015) Treatment with anti-toxoplasmic activity (TATA) for Toxoplasma positive patients with bipolar disorders or schizophrenia: a cross-sectional study. J Psychiatr Res 63:58\u201364. doi: 10.1016\/j.jpsychires.2015.02.011","journal-title":"J Psychiatr Res"},{"key":"5478_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00406-013-0413-4","volume":"264","author":"G Fond","year":"2014","unstructured":"Fond G, Macgregor A, Tamouza R et al (2014) Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate. Eur Arch Psychiatry Clin Neurosci 264:179\u2013183. doi: 10.1007\/s00406-013-0413-4","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"5478_CR21","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.pnpbp.2007.08.031","volume":"32","author":"Y Fujita","year":"2008","unstructured":"Fujita Y, Ishima T, Kunitachi S et al (2008) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuro-Psychopharmacol Biol Psychiatry 32:336\u2013339. doi: 10.1016\/j.pnpbp.2007.08.031","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"5478_CR22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1645\/GE-2536.1","volume":"97","author":"DG Goodwin","year":"2011","unstructured":"Goodwin DG, Strobl JS, Lindsay DS (2011) Evaluation of five antischizophrenic agents against Toxoplasma gondii in human cell cultures. J Parasitol 97:148\u2013151. doi: 10.1645\/GE-2536.1","journal-title":"J Parasitol"},{"key":"5478_CR23","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1021\/jm901857d","volume":"53","author":"CP Hencken","year":"2010","unstructured":"Hencken CP, Jones-Brando L, Bord\u00f3n C et al (2010) Thiazole, oxadiazole, and carboxamide derivatives of artemisinin are highly selective and potent inhibitors of Toxoplasma gondii. J Med Chem 53:3594. doi: 10.1021\/jm901857d","journal-title":"J Med Chem"},{"key":"5478_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/acps.12031","volume":"127","author":"D Holub","year":"2013","unstructured":"Holub D, Flegr J, Dragomireck\u00e1 E et al (2013) Differences in onset of disease and severity of psychopathology between toxoplasmosis-related and toxoplasmosis-unrelated schizophrenia. Acta Psychiatr Scand 127:227\u2013238. doi: 10.1111\/acps.12031","journal-title":"Acta Psychiatr Scand"},{"key":"5478_CR25","first-page":"37","volume":"15","author":"D Holub","year":"2011","unstructured":"Holub D, Motlov\u00e1 L, Dragomireck\u00e1 E et al (2011) Possible protective function of Rh factor in schizophrenia. Psychiatrie 15:37\u201342","journal-title":"Psychiatrie"},{"key":"5478_CR26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3109\/15622975.2011.573809","volume":"13","author":"J Horacek","year":"2012","unstructured":"Horacek J, Flegr J, Tintera J et al (2012) Latent toxoplasmosis reduces gray matter density in schizophrenia but not in controls: voxel-based-morphometry (VBM) study. World J Biol Psychiatry 13:501\u2013509. doi: 10.3109\/15622975.2011.573809","journal-title":"World J Biol Psychiatry"},{"key":"5478_CR27","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1093\/infdis\/164.1.170","volume":"164","author":"J Huskinson-Mark","year":"1991","unstructured":"Huskinson-Mark J, Araujo FG, Remington JS (1991) Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis 164:170\u2013171. doi: 10.1093\/infdis\/164.1.170","journal-title":"J Infect Dis"},{"key":"5478_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0920-9964(02)00357-2","volume":"62","author":"L Jones-Brando","year":"2003","unstructured":"Jones-Brando L, Torrey EF, Yolken R (2003) Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res 62:237\u2013244. doi: 10.1016\/S0920-9964(02)00357-2","journal-title":"Schizophr Res"},{"key":"5478_CR29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/0035-9203(58)90123-8","volume":"52","author":"R Lainson","year":"1958","unstructured":"Lainson R (1958) Observations on the development and nature of pseudocysts and cysts of Toxoplasma gondii. Trans R Soc Trop Med Hyg 52:396\u2013407. doi: 10.1016\/0035-9203(58)90123-8","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"5478_CR30","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","volume":"79","author":"S Leucht","year":"2005","unstructured":"Leucht S, Kane JM, Kissling W et al (2005) What does the PANSS mean? Schizophr Res 79:231\u2013238. doi: 10.1016\/j.schres.2005.04.008","journal-title":"Schizophr Res"},{"key":"5478_CR31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.14411\/fp.2010.017","volume":"57","author":"J Lindov\u00e1","year":"2013","unstructured":"Lindov\u00e1 J, Kub\u011bna AA, \u0160turcov\u00e1 H et al (2013) Pattern of money allocation in experimental games supports the stress hypothesis of gender differences in Toxoplasma gondii-induced behavioural changes. Folia Parasitol 57:136\u2013142. doi: 10.14411\/fp.2010.017","journal-title":"Folia Parasitol"},{"key":"5478_CR32","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1016\/j.ijpara.2006.07.008","volume":"36","author":"J Lindov\u00e1","year":"2006","unstructured":"Lindov\u00e1 J, Novotn\u00e1 M, Havl\u00edcek J et al (2006) Gender differences in behavioural changes induced by latent toxoplasmosis. Int J Parasitol 36:1485\u20131492. doi: 10.1016\/j.ijpara.2006.07.008","journal-title":"Int J Parasitol"},{"key":"5478_CR33","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.phrs.2016.11.012","volume":"117","author":"CSN Loo","year":"2017","unstructured":"Loo CSN, Lam NSK, Yu D et al (2017) Artemisinin and its derivatives in treating protozoan infections beyond malaria. Pharmacol Res 117:192\u2013217. doi: 10.1016\/j.phrs.2016.11.012","journal-title":"Pharmacol Res"},{"key":"5478_CR34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33899\/iphr.2006.50532","volume":"6","author":"SS Mahmoud","year":"2006","unstructured":"Mahmoud SS (2006) Azithromycin macrolids with a potent activity on chronic experimental toxopiasmosis. Iraqi J Pharm 6:1\u20135","journal-title":"Iraqi J Pharm"},{"key":"5478_CR35","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1093\/schbul\/sbu159","volume":"41","author":"JM Monroe","year":"2015","unstructured":"Monroe JM, Buckley PF, Miller BJ (2015) Meta-analysis of anti-Toxoplasma gondii IgM antibodies in acute psychosis. Schizophr Bull 41:989\u2013998. doi: 10.1093\/schbul\/sbu159","journal-title":"Schizophr Bull"},{"key":"5478_CR36","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ejps.2010.05.016","volume":"41","author":"V Muni\u0107","year":"2010","unstructured":"Muni\u0107 V, Kelneri\u0107 \u017d, Mikac L, Erakovi\u0107 Haber V (2010) Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci 41:86\u201395. doi: 10.1016\/j.ejps.2010.05.016","journal-title":"Eur J Pharm Sci"},{"key":"5478_CR37","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"AB Nair","year":"2016","unstructured":"Nair AB, Jacob S (2016) A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm 7:27\u201331. doi: 10.4103\/0976-0105.177703","journal-title":"J Basic Clin Pharm"},{"key":"5478_CR38","doi-asserted-by":"publisher","first-page":"7161","DOI":"10.1128\/AAC.02009-15","volume":"59","author":"AJ Neville","year":"2015","unstructured":"Neville AJ, Zach SJ, Wang X et al (2015) Clinically available medicines demonstrating anti-Toxoplasma activity. Antimicrob Agents Chemother 59:7161\u20137169. doi: 10.1128\/AAC.02009-15","journal-title":"Antimicrob Agents Chemother"},{"key":"5478_CR39","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1111\/j.1476-5381.1983.tb10537.x","volume":"79","author":"B Nguyen","year":"1983","unstructured":"Nguyen B, Stadtsbaeder S (1983) Comparative effects of cotrimoxazole (trimethoprim-sulphamethoxazole), pyrimethamine-sulphadiazine and spiramycin during avirulent infection with Toxoplasma gondii (Beverley strain) in mice. Br J Pharmacol 79:923\u2013928. doi: 10.1111\/j.1476-5381.1983.tb10537.x","journal-title":"Br J Pharmacol"},{"key":"5478_CR40","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/hup.2426","volume":"29","author":"K Oya","year":"2014","unstructured":"Oya K, Kishi T, Iwata N (2014) Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol 29:483\u2013491. doi: 10.1002\/hup.2426","journal-title":"Hum Psychopharmacol"},{"key":"5478_CR41","unstructured":"Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents (2017) Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. https:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/adult_oi.pdf . Accessed 18 Feb 2017"},{"key":"5478_CR42","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.ijpara.2009.04.003","volume":"39","author":"G Pappas","year":"2009","unstructured":"Pappas G, Roussos N, Falagas ME (2009) Toxoplasmosis snapshots: global status of Toxoplasma gondii seroprevalence and implications for pregnancy and congenital toxoplasmosis. Int J Parasitol 39:1385\u20131394. doi: 10.1016\/j.ijpara.2009.04.003","journal-title":"Int J Parasitol"},{"key":"5478_CR43","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1128\/CMR.14.3.476-488.2001","volume":"14","author":"CW Roberts","year":"2001","unstructured":"Roberts CW, Walker W, Alexander J (2001) Sex-associated hormones and immunity to protozoan parasites. Clin Microbiol Rev 14:476\u2013488. doi: 10.1128\/CMR.14.3.476-488.2001","journal-title":"Clin Microbiol Rev"},{"key":"5478_CR44","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1128\/AAC.41.7.1531","volume":"41","author":"ME Sarciron","year":"1997","unstructured":"Sarciron ME, Lawton P, Saccharin C et al (1997) Effects of 2\u2032,3\u2032-dideoxyinosine on Toxoplasma gondii cysts in mice. Antimicrob Agents Chemother 41:1531\u20131536","journal-title":"Antimicrob Agents Chemother"},{"key":"5478_CR45","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1645\/13-451.1","volume":"100","author":"TL Schultz","year":"2014","unstructured":"Schultz TL, Hencken CP, Woodard LE et al (2014) A thiazole derivative of artemisinin moderately reduces Toxoplasma gondii cyst burden in infected mice. J Parasitol 100:516\u2013521. doi: 10.1645\/13-451.1","journal-title":"J Parasitol"},{"key":"5478_CR46","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1139\/cjpp-2016-0039","volume":"94","author":"M Sharif","year":"2016","unstructured":"Sharif M, Sarvi S, Pagheh AS et al (2016) The efficacy of herbal medicines against Toxoplasma gondii during the last 3 decades: a systematic review. Can J Physiol Pharmacol 94:1237\u20131248. doi: 10.1139\/cjpp-2016-0039","journal-title":"Can J Physiol Pharmacol"},{"key":"5478_CR47","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1093\/schbul\/sbn191","volume":"36","author":"T Shibre","year":"2010","unstructured":"Shibre T, Alem A, Abdulahi A et al (2010) Trimethoprim as adjuvant treatment in schizophrenia: a double-blind, randomized, placebo-controlled clinical trial. Schizophr Bull 36:846\u2013851. doi: 10.1093\/schbul\/sbn191","journal-title":"Schizophr Bull"},{"key":"5478_CR48","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1128\/AAC.48.3.809-814.2004","volume":"48","author":"M Sugie","year":"2004","unstructured":"Sugie M, Asakura E, Zhao YL et al (2004) Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother 48:809\u2013814. doi: 10.1128\/AAC.48.3.809-814.2004","journal-title":"Antimicrob Agents Chemother"},{"key":"5478_CR49","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/acps.12423","volume":"132","author":"AL Sutterland","year":"2015","unstructured":"Sutterland AL, Fond G, Kuin A et al (2015) Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. Acta Psychiatr Scand 132:161\u2013179. doi: 10.1111\/acps.12423","journal-title":"Acta Psychiatr Scand"},{"key":"5478_CR50","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","volume":"388","author":"T Vos","year":"2016","unstructured":"Vos T, Allen C, Arora M et al (2016) Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388:1545\u20131602. doi: 10.1016\/S0140-6736(16)31678-6","journal-title":"Lancet"},{"key":"5478_CR51","doi-asserted-by":"publisher","unstructured":"Wang HL, Wang GH, Li QW et al (2006) Prevalence of Toxoplasma infection in first-episode schizophrenia and comparison between Toxoplasma-seropositive and Toxoplasma-seronegative schizophrenia. Acta Psychiatr Scand 114:40\u201348. doi: 10.1111\/j.1600-0447.2006.00780.x","DOI":"10.1111\/j.1600-0447.2006.00780.x"},{"key":"5478_CR52","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jpsychires.2014.02.016","volume":"53","author":"HL Wang","year":"2014","unstructured":"Wang HL, Xiang YT, Li QY et al (2014) The effect of artemether on psychotic symptoms and cognitive impairment in first-episode, antipsychotic drug-naive persons with schizophrenia seropositive to Toxoplasma gondii. J Psychiatr Res 53:119\u2013124. doi: 10.1016\/j.jpsychires.2014.02.016","journal-title":"J Psychiatr Res"},{"key":"5478_CR53","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1098\/rspb.2005.3413","volume":"273","author":"JP Webster","year":"2006","unstructured":"Webster JP, Lamberton PHL, Donnelly CA, Torrey EF (2006) Parasites as causative agents of human affective disorders? The impact of anti-psychotic, mood-stabilizer and anti-parasite medication on Toxoplasma gondii\u2019s ability to alter host behaviour. Proc R Soc Lond B Biol Sci 273:1023\u20131030. doi: 10.1098\/rspb.2005.3413","journal-title":"Proc R Soc Lond B Biol Sci"}],"container-title":["Parasitology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00436-017-5478-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-017-5478-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00436-017-5478-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T16:10:53Z","timestamp":1659024653000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00436-017-5478-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,15]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["5478"],"URL":"https:\/\/doi.org\/10.1007\/s00436-017-5478-y","relation":{},"ISSN":["0932-0113","1432-1955"],"issn-type":[{"value":"0932-0113","type":"print"},{"value":"1432-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,15]]}}}